Healthy Volunteers Clinical Trial
Official title:
Investigation of Dietary Absorptive Capacity of Fructans in Healthy Subjects - A Randomized, Double-Blind Dose Response Study
| NCT number | NCT00988403 |
| Other study ID # | Fructan |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | June 2009 |
| Est. completion date | July 20, 2018 |
| Verified date | July 2018 |
| Source | Augusta University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Fructan is a carbohydrate polymer that is composed of fructose and a terminal glucose moiety
. Fructans are naturally found in artichokes (6.1 grams/serving), leeks (5.9 grams/serving),
onion bulbs (1.01 grams/serving), flour (4.0 grams/serving), garlic (.52 grams/serving),
watermelon (.92 grams/serving), nectarines (.27 grams/serving) and white peaches (.50
grams/serving). Because fructans are present in many common foods, people typically ingest
high levels of fructan. The most common structural forms of fructan are inulin, levanare and
geraminan . The human body absorbs only 5% of fructan, however it is estimated that the daily
intake in the USA may vary between 1-20 grams, and possibly higher due to the recently
discovered benefits of inulins . Dietary trends indicate that high levels of fructans are
common in the European and American diet, as more wheat based products such as breakfast
cereal, pasta, and bread are consumed.
Fructans may not be well tolerated by some subjects and its malabsorption may result in
gastrointestinal (GI) symptoms such as heartburn, belching, abdominal pain, diarrhea, gas,
and bloating; and this is especially true when higher doses are ingested. Unlike glucose,
fructans are not efficiently digested or absorbed by the small intestine. The mechanism for
malabsorption is related to the inability to hydrolyze glycosidic linkages in the complex
polysaccharide, resulting in the delivery of malabsorbed fructans to the large bowel1. In the
colon, the malabsorbed fructans are rapidly fermented, and byproducts of this fermentation
include H2, CH4, and other gases that may contribute to bowel symptoms. Furthermore, the
small molecular nature of fructans results in an osmotic effect which draws more water into
the small intestine and causes bloating and diarrhea.
Ingestion of high doses of fructans can cause symptoms in healthy adults, but may cause more
bothersome symptoms in subjects with Irritable Bowel Syndrome (IBS). Earlier studies have
identified that IBS affects between 10 and 15% of the population in the United States.
Ingestion of 10-20 grams of fructan daily may cause symptoms of IBS, and restricting fructan
intake in a diet may reduce symptoms in a variety of gastrointestinal disorders. One study
recently published found that dietary restriction of fructan and fructose was responsible for
symptomatic improvement in patients with IBS.
Hypothesis:
The investigators hypothesize that healthy individuals will absorb fructan 7.5 gram and 10
gram doses, and will experience malabsorption at the 12.5 gram fructan dose.
| Status | Completed |
| Enrollment | 19 |
| Est. completion date | July 20, 2018 |
| Est. primary completion date | August 31, 2011 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 99 Years |
| Eligibility |
Inclusion Criteria: - Healthy volunteers between the ages of 18-70 years, with no previous history of gastrointestinal problems or any other ailments, no history of gastrointestinal surgery except appendectomy, cholecystectomy, caesarean section, hysterectomy and currently not using any medication except contraceptive pill, multivitamin, or aspirin. - They will be asked to fill out a Review of Systems health history (Appendix 2) and the Mayo Clinic Bowel Disease Questionnaire (Appendix 3) and will undergo a routine physical examination. Only patients who are asymptomatic and deemed healthy from the aforementioned screening procedure will be eligible. Exclusion Criteria: - Currently taking medication for any ailment including OTC medication (excluding aspirin, multivitamins, and oral contraceptives) - History of gastrointestinal problems including bloating, gas, food intolerances or reflux symptoms - Any major abdominal surgery (except appendectomy, cholecystectomy, caesarean section, hysterectomy) or coexisting medical problem - Known food allergies - Prisoners - Cognitive Impairment or any other inability to provide informed consent |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
| Lead Sponsor | Collaborator |
|---|---|
| Augusta University | American Gastroenterological Association Foundation |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Hydrogen and Methane Concentration levels | Measure breath sample concentration for hydrogen and methane levels in parts per million | 3 visits over a 1 month period | |
| Secondary | Production of GI Symptoms | Production of bothersome GI symptoms such as gas, bloating, cramping or abdominal pain during breath test. Symptoms were mesured using a validated symptom questionnaire. | 3 visits over a 1 month period |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |